Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Learn About Methods for Making Long and Complex Peptides | Contract Pharma

What are you searching for?

Sign in
Sponsored Content

Learn About Methods for Making Long and Complex Peptides

The pros and cons of today’s technologies for SPPS, native chemical ligation, CEPS, KAHA and recombinant technologies.

Released By Bachem

Which of the current available production techniques should be chosen for long, complex and functionalized peptides or even small proteins? Which technologies allow functionalization of peptides? Get answers to these questions by joining our next webinar where experts are discussing the pros and cons of today’s technologies for SPPS, native chemical ligation, CEPS, KAHA and recombinant technologies. Submit your questions to our experts prior to the webinar via email (webinar@bachem.com). Additionally, you can ask your questions either during the Q&A session of the webinar or in a discussion round afterwards (link to be provided during webinar).

Speakers:

Dr. Leendert Van Den Bos – CEO at EnzyTag BV

Dr. Leendert van den Bos obtained his MSc- and PhD-degree in bio-organic chemistry from Leiden University. In 2007, he joined Organon BioSciences as a Scientist and worked subsequently for Schering-Plough, Merck Sharp & Dohme and Aspen Pharmacare mostly in the field of Process Research & Development. In 2018 he co-founded EnzyTag focusing on the development of chemo-enzymatic processes for complex peptide API’s. Leendert holds an Executive MBA from Nyenrode University.

Naoki Yamamoto – Head of Business Development, Asia Pacific

Naoki Yamamoto has been Head of Business Development & Sales, Asia Pacific at Bachem Japan since Jan 2022. For the past 16 years, he’s been involved in the development of new synthetic methodologies for glycopeptides and glycoproteins, purification & analytical technologies for those materials, and coordinating several collaborations and alliances with not only domestic pharma companies but also international pharms. Prior to joining Bachem Japan, he was RAQA & BD Director at 3-D Matrix (2017-2021), and a regional president at Brand Institute (2015-2016). Prior to Brand Institute, he served as a Senior Investigator at GlyTech (2012-2014) and American Peptide Company, Sunnyvale, California in the US (2009-2012). Prior to American Peptide Company, he was a Researcher at Otsuka Chemical Company (2006-2009). He received his Ph.D. degree in Chemistry from Yokohama City University, Japan in 2006.

Register Now!

Request more information from Bachem

Request more information from Bachem

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics